InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,307.01
(
-0.27%
)
US TECH 100
18,381.60
(
0.84%
)
Dow Jones
39,671.04
(
-0.51%
)
Brent Oil
81.87
(
0.41%
)
Bitcoin
69,555.25
(
0.65%
)
Post# of 251903
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119681
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 177518

Saturday, 05/03/2014 1:20:48 PM

Saturday, May 03, 2014 1:20:48 PM

Post# of 251903
AZN took only four hours to reject PFE’s sweetened offer of $84.47/sh*:

http://online.wsj.com/news/articles/SB10001424052702303678404579536931759280594

AstraZeneca PLC on Friday rejected an improved takeover offer from Pfizer Inc. worth more than $106 billion, saying the proposal substantially undervalued the company and putting the onus back on Pfizer Chief Executive Ian Read to either raise his bid again, go directly to shareholders, or walk away.

The sweetened offer of 1.845 shares in the combined company and £15.98 ($26.96) in cash for each share of AZN is about 7% better than the offer PFE made in Jan 2014 and disclosed a few days ago.

*$84.47 nominal value is based on the current exchange rate and PFE’s closing price of $31.15 on 5/1/14.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up